The Pleural Effusion drugs in development market research report provides comprehensive information on the therapeutics under development for Pleural Effusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pleural Effusion. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pleural Effusion and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Pleural Effusion by 13 companies/universities/institutes. The top development phase for Pleural Effusion is phase i with six drugs in that stage. The Pleural Effusion pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Pleural Effusion pipeline products market are: Amgen, Genelux and Simcere Pharmaceutical Group.
The key targets in the Pleural Effusion pipeline products market include Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA), Dihydrofolate Reductase (DHFR or EC 1.5.1.3), and CD3 .
The key mechanisms of action in the Pleural Effusion pipeline product include Dihydrofolate Reductase (DHFR or EC 1.5.1.3) Inhibitor with one drug in Phase II. The Pleural Effusion pipeline products include ten routes of administration with the top ROA being Intrapleural and seven key molecule types in the Pleural Effusion pipeline products market including Small Molecule, and Oncolytic Virus.
Pleural Effusion overview
Pleural Effusion also known as fluid in lungs is a condition where accumulation of fluid in pleural space of lungs observed. Underlying disease conditions of the lungs like pneumonia, emphysema, TB, etc, and other conditions like CKD, heart failure, and pancreatitis can also cause pleural effusion, and sometimes the etiology is unknown. It is usually classified as transudates and exudates. Normal pleural fluid count in healthy individuals is 0.1 ml/kg to 0.3 ml/kg and is constantly exchanged any disturbance in this exchange can result in this condition. Symptoms can be predictable or asymptomatic but, in most cases, we observe breathlessness, difficulty during cough, sometimes presented with fever, and other systematic symptoms. Chest radiography is performed to diagnose this condition and others like fluid pH, fluid protein, albumin and LDH, fluid glucose, fluid triglyceride, fluid cell count differential, fluid gram stain and culture, and fluid cytology. Treatment is based on targeting the cause. If it is caused by underlying tuberculosis antibiotic therapy is preferred. In complicated cases, fluid drainage is done and, in some cases, surgery is chosen.
For a complete picture of Pleural Effusion’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
